These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 17927446)

  • 1. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
    Gong Y; Somwar R; Politi K; Balak M; Chmielecki J; Jiang X; Pao W
    PLoS Med; 2007 Oct; 4(10):e294. PubMed ID: 17927446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
    Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
    Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
    Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
    Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
    Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
    Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
    Takeuchi S; Yano S
    Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
    Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PUMA and BIM are required for oncogene inactivation-induced apoptosis.
    Bean GR; Ganesan YT; Dong Y; Takeda S; Liu H; Chan PM; Huang Y; Chodosh LA; Zambetti GP; Hsieh JJ; Cheng EH
    Sci Signal; 2013 Mar; 6(268):ra20. PubMed ID: 23532334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
    Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
    Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
    Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
    Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
    Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
    Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
    Dogan I; Kawabata S; Bergbower E; Gills JJ; Ekmekci A; Wilson W; Rudin CM; Dennis PA
    Lung Cancer; 2014 Jul; 85(1):1-6. PubMed ID: 24746758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.